Valeant Pharmaceuticals Intl Inc  

(Public, NYSE:VRX)   Watch this stock  
Find more results for NYSE:BVF
120.94
+0.26 (0.22%)
Real-time:   12:41PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 119.08 - 121.40
52 week 89.76 - 153.10
Open 120.32
Vol / Avg. 607,102.00/3.45M
Mkt cap 40.34B
P/E     -
Div/yield     -
EPS -2.58
Shares 333.57M
Beta 0.86
Inst. own 86%
Aug 4, 2014
Q2 2014 Valeant Pharmaceuticals International, Inc. Earnings Release (Estimated) Add to calendar
Jun 17, 2014
Valeant Pharmaceuticals International Inc Conference Call to Correct Recent Misrepresentations
Jun 2, 2014
Valeant Pharmaceuticals International, Inc. Conference Call to Discuss Revised Offer for Allergan
May 28, 2014
Valeant Pharmaceuticals International, Inc. at Sanford C Bernstein Strategic Decisions Conference
May 28, 2014
Valeant Pharmaceuticals International, Inc. Investor Meeting to Discuss the Merger Proposal with Allergan Conference Call
May 20, 2014
Valeant Pharmaceuticals International, Inc. Annual Shareholder Meeting - Webcast
May 12, 2014
Allergan Conference Call to discuss the Rejection of Unsolicited Proposal from Valeant Pharmaceuticals International, Inc
May 8, 2014
Q1 2014 Valeant Pharmaceuticals International, Inc. Earnings Release
May 8, 2014
Q1 2014 Valeant Pharmaceuticals International, Inc. Earnings Conference Call
Apr 22, 2014
Valeant Pharmaceuticals International, Inc. Conference Call to Discuss the Proposed Acquisition of Allergan
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -1.08% -14.97%
Operating margin 13.94% -8.22%
EBITD margin - 51.28%
Return on average assets -0.29% -3.76%
Return on average equity -1.78% -19.60%
Employees 17,200 -
CDP Score - -

Address

2150 ST. ELZEAR BLVD. WEST
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company operates in five business segments: U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded Generics - Europe and Branded Generics -Latin America. Within its U.S. Dermatology segment and Branded Generic - Europe segment the Company generates service revenue from contract services in the areas of dermatology and topical medication. In June 2014, Akorn Inc sold its subsidiary, ECR Pharmaceuticals (ECR) to Valeant Pharmaceuticals International, Inc. In July 2014, the Company acquired PreCision Dermatology, Inc.